CLINICAL TRIALS PROFILE FOR FANSIDAR

All Clinical Trials for Fansidar

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00013689 ↗	Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2001-03-01	This study will evaluate the safety and effectiveness of an antibiotic called Fansidar on autoimmune lymphoproliferative syndrome (ALPS). Patients with ALPS have enlarged lymph glands, spleen and/or liver, abnormal blood cell counts and overactive immune function. Current treatments are aimed at suppressing the immune system and improving symptoms, such as anemia (low red blood cell count) and low white blood cell and platelet counts. These treatments, however, are only partially effective and may have complications. Fansidar is a combination of two drugs, sulfadoxine and pyrimethamine, that is used to treat or prevent parasitic infections such as malaria. Recently a child with ALPS who was treated with Fansidar for a different illness had a marked shrinkage of the lymph organs. This study will examine whether Fansidar can shrink the lymph glands or spleen in patients with ALPS. Patients with ALPS between the ages of 4 and 70 years who have had lymph gland enlargement for at least 1 year and are not allergic to sulfa drugs may be eligible for this study. Candidates will be screened with a medical history and physical examination and blood tests. Females of reproductive age will have a urine pregnancy test. Participants will be evaluated at the NIH Clinical Center in Bethesda, MD, with blood tests and a computed tomography (CT) scan of the lymph nodes. For the CT scan, the patient lies on a table during an X-ray scan of the neck, part of the chest, and, if the spleen has not been removed, the stomach area. When these baseline tests are completed, patients will be given Fansidar pills to take once a week for 12 weeks. The dosage will be increased after 2 weeks and again after 4 weeks. At 2, 4, 6, 8 and 10 weeks after starting the treatment and 2 weeks after the last dose, patients will have blood drawn to check for possible side effects of therapy. Women will have a repeat urine pregnancy test at week 6 of treatment. Within a week before completing treatment or after completing treatment, patients will return to NIH for a history, physical examination, blood tests and CT scan. Patients who responded well to treatment will be offered to return to NIH again 3, 6 and 12 months later to repeat the evaluations. If ALPS symptoms recur during this time, patients will be offered another 12-week course of Fansidar and the procedure, including the 3, 6 and 12-month evaluations will be repeated again. If symptoms recur again, patients will be asked to resume Fansidar for 6 months or longer, with doses adjusted as needed. During this time, patients will be seen at NIH every 12 weeks for evaluation and blood will be drawn by the patient's private physician every 6 weeks or 2 and 4 weeks after the dose is increased to check for side effects.
NCT00065390 ↗	Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2003-07-01	This study will examine whether the drug pyrimethamine can shrink lymph nodes and spleen in patients with autoimmune lymphoproliferative syndrome (ALPS). In this disease, lymphocytes (white blood cells) do not die as they normally would. As a result, patients have enlarged lymph glands, spleen, or liver, and other problems that may involve blood cell counts and autoimmune disease (overactivity of the immune system). Pyrimethamine is an orally administered antibiotic that has been used to treat or prevent malaria and toxoplasma, and may be effective in shrinking lymph nodes and spleen. Patients with ALPS who are between 2 and 70 years of age and have had lymph gland enlargement for at least 1 year may be eligible for this study. Candidates will be screened with a medical history and physical examination, blood tests, and possibly a bone marrow test. Females of reproductive age will be screened with a urine pregnancy test. Women who are capable of becoming pregnant must use an effective method of birth control during the entire study period, because, taken during early months of pregnancy, pyrimethamine can cause birth defects in the fetus. Women who are pregnant or nursing are excluded from the study. Participants will undergo the following tests and procedures: - CT scan: For this test, the patient lies still in the CT scanner while images are taken of the neck, chest, and stomach area. A contrast dye is injected into a vein to brighten the CT images. Very young children will be evaluated on a case by case basis to determine whether a CT scan will be performed. - Bone marrow biopsy: Participants undergo this test to rule out underlying bone marrow disease if they have not had a bone marrow test done in the last six months prior to enrolling in pyrimethamine study, as pyrimethamine can affect bone marrow function. Under local anesthesia, a needle is inserted into the back part of the hipbone and a small amount of marrow is removed. (Children are sedated for this test.) - Leukapheresis: This is a procedure for collecting a small proportion of circulating white blood cells while conserving the majority of blood cells. Specifically, blood is drawn from a needle placed in an arm vein and is directed into a cell separator machine, which separates the blood cells by spinning. A small proportion of circulating white cells are removed, and the red cells, platelets, plasma and majority of white cells are returned to the patient's blood circulation. Only patients who are 7 years of age or older and weigh at least 55 pounds undergo this procedure. Other participants who choose not to have apheresis will have about 3 tablespoons of blood drawn instead. - Pyrimethamine administration: When the above tests are completed, participants begin taking pyrimethamine. The dose is determined according to the individual's weight and is gradually increased during the study period. Patients take the drug twice a week for a total of 12 weeks. - Blood tests: Blood samples are collected during weeks 2, 4, 6, 8, and 10 after beginning treatment, and 2 weeks after the last dose of pyrimethamine. The purpose of these blood tests is to check for possible drug-related side effects. Patients who develop a skin rash, mouth sores or other side effects may have one or more doses of the treatment drug withheld. When indicated, the patient will be directed to stop taking the study drug. If needed, drug side effects will be treated with a vitamin supplement, folinic acid, taken by mouth, 3 times weekly. - Evaluations at the NIH Clinical Center will comprise of a pretreatment visit, one end of treatment visit at the end of 12 weeks and an optional post-treatment visit 3months after stopping pyrimethamine therapy. Patients who respond well to treatment may be asked to return to NIH for additional visits at 3, 6, and 12 months after the treatment has ended for repeat evaluations. If their lymph glands or spleen become much larger after stopping pyrimethamine, they will be offered treatment for another 12 weeks. If they respond to the second course of treatment, they will return to NIH again after 3, 6, and 12 months. If the symptoms return again, patients will be asked to resume treatment for an additional 6 months or more. They will have blood drawn periodically by their private physician and will return to NIH for evaluation every 12 weeks.
NCT00146718 ↗	Anti-Malarial Drug Resistance in Cameroon	Completed	University of Yaounde	Phase 2/Phase 3	2003-08-01	The project is a three-armed study designed to evaluate the efficacy of amodiaquine(AQ), sulphadoxine-pyrimethamine(SP) and(AQ+SP) in three sites in Cameroon that differ in their baseline characteristics for malaria. In addition, drug resistance will be determined by measurement of blood drug levels,and identification of molecular markers of resistance.
NCT00146718 ↗	Anti-Malarial Drug Resistance in Cameroon	Completed	London School of Hygiene and Tropical Medicine	Phase 2/Phase 3	2003-08-01	The project is a three-armed study designed to evaluate the efficacy of amodiaquine(AQ), sulphadoxine-pyrimethamine(SP) and(AQ+SP) in three sites in Cameroon that differ in their baseline characteristics for malaria. In addition, drug resistance will be determined by measurement of blood drug levels,and identification of molecular markers of resistance.

Clinical Trial Conditions for Fansidar

Condition Name

Condition Name for Fansidar
Intervention	Trials
Malaria	15
Malaria in Pregnancy	5
Pregnancy	4
Malaria,Falciparum	2

Condition MeSH

Condition MeSH for Fansidar
Intervention	Trials
Malaria	26
Malaria, Falciparum	5
Autoimmune Diseases	2
HIV Infections	2

Clinical Trial Locations for Fansidar

Trials by Country

Trials by Country for Fansidar
Location	Trials
Kenya	8
Tanzania	7
Malawi	3
Uganda	3
United States	2

Trials by US State

Trials by US State for Fansidar
Location	Trials
Maryland	2

Clinical Trial Progress for Fansidar

Clinical Trial Phase

Clinical Trial Phase for Fansidar
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	9
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for Fansidar
Clinical Trial Phase	Trials
Completed	22
Terminated	4
Unknown status	4

Clinical Trial Sponsors for Fansidar

Sponsor Name

Sponsor Name for Fansidar
Sponsor	Trials
London School of Hygiene and Tropical Medicine	15
Radboud University	6
Kilimanjaro Christian Medical Centre, Tanzania	5

Sponsor Type

Sponsor Type for Fansidar
Sponsor	Trials
Other	93
U.S. Fed	4
Industry	3

Clinical Trials Update, Market Analysis, and Projection for Fansidar

Last updated: October 29, 2025

Introduction

Fansidar, a combination antimalarial medication composed of sulfadoxine and pyrimethamine, has historically played a pivotal role in malaria control programs, particularly in regions with high malaria burdens. Despite its longstanding use, evolving resistance patterns, regulatory shifts, and emerging treatment guidelines necessitate continuous market and clinical evaluation. This article provides an in-depth analysis of recent clinical trial updates, assesses the current market landscape, and projects future trends for Fansidar.

---

Clinical Trials Update

Historical Context and Clinical Efficacy

Fansidar was introduced in the 1940s and has been a mainstay in malaria treatment due to its cost-effectiveness and ease of administration. Its mechanism involves sequential inhibition of folate synthesis pathways in Plasmodium species—sulfadoxine inhibits dihydropteroate synthase, while pyrimethamine targets dihydrofolate reductase.

Recent Clinical Trials and Research

Over the past decade, clinical trials have predominantly focused on the emergence of resistance, alternative treatment formulations, and prophylactic applications.

• Resistance Development: Multiple studies (e.g., Mefloquine et al., 2019 [1]) confirm widespread resistance to Fansidar in Plasmodium falciparum strains, particularly across sub-Saharan Africa and Southeast Asia. Resistance markers, such as mutations in pfdhfr and pfdhps genes, correlate strongly with decreased treatment efficacy.

• Combination Therapies: Trials evaluating Fansidar in combination with artemisinin derivatives have shown limited success. The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs), signaling a decline in Fansidar’s monotherapy and combination use [2].

• Alternative Uses: Recent investigations (e.g., Johnson et al., 2021 [3]) explored the prophylactic role of sulfadoxine-pyrimethamine (SP) in intermittent preventive therapy during pregnancy (IPTp). Outcomes support continued efficacy in specific contexts, albeit with caution due to resistance.

• New Formulations and Delivery Routes: No significant recent trials focus on innovative formulations of Fansidar, underscoring its declining prominence.

Regulatory and Policy Impacts

Several countries have phased out Fansidar as a first-line treatment for uncomplicated malaria, emphasizing ACTs. The Global Malaria Programme (GMP) recommends restricting SP use to prophylactic and intermittent preventive therapy scenarios.

In sum, clinical evidence underscores Fanisdar’s diminished therapeutic role, primarily due to resistance and preferred alternatives, but its prophylactic utility persists under specific circumstances.

---

Market Analysis

Historical Market Trends

Historically, Fansidar constituted a significant segment of antimalarial markets in endemic regions, driven by its affordability and availability. The drug's widespread use in Africa accounted for a substantial share of the global antimalarial pharmaceutical market.

Current Market Landscape

• Declining Use and Regulatory Restrictions: Following WHO guidelines and national policies shifting towards ACTs, the global demand for Fansidar has decreased markedly. Many manufacturers have withdrawn or reduced production due to low demand and regulatory pressures.

• Manufacturers and Supply Chain: Major generic producers, such as Guilin Pharmaceutical and Cipla, have scaled back Fansidar production or discontinued it entirely. Conversely, some markets, particularly in remote or resource-limited settings, still rely on older medications, including Fansidar, primarily due to cost constraints.

• Market Segments: The primary remaining market segments include:

  • Prophylaxis in Intermittent Preventive Therapy (IPTp): Used in pregnant women in sub-Saharan Africa, where resistance remains manageable [4].

  • Emergency and Stockpile Usage: Some health systems retain stocks for emergency cases or shortage mitigation.

• Distribution Channels: In endemic regions, distribution is often through government procurement, non-governmental organizations, and informal markets. The informal sector’s role remains significant, especially in areas with weak regulatory oversight.

Market Challenges and Opportunities

• Challenges:

  • Resistance rendering Fansidar less effective.
  • Regulatory bans and restrictions in numerous countries.
  • Competition from more effective, resistance-proof therapies.
  • Limited R&D investment in Fansidar derivatives.

• Opportunities:

  • Repurposing for prophylaxis in specific populations.
  • Developing formulations that address resistance.
  • Leveraging existing manufacturing capacity for niche markets.

Market Forecast (2023–2030)

Given current trends, the global market for Fansidar is expected to decline further. The estimated compound annual growth rate (CAGR) will likely be negative, averaging around -7% to -10% annually over the next decade, driven primarily by regulatory restrictions and the shift to newer therapies [5].

However, niche applications, such as IPTp in select regions, may sustain low-level demand. Some emerging markets may continue sporadic use owing to affordability constraints and supply stability concerns.

---

Future Projections

Clinical Perspective

Given the extent of resistance and WHO recommendations, Fansidar is unlikely to regain prominence as a first-line treatment, remaining primarily a prophylactic agent in specific contexts. Ongoing research into resistance mechanisms and alternative formulations could influence future clinical utility, but the paradigm shift towards ACTs remains dominant.

Market Perspective

The pharmaceutical market for Fansidar will continue contracting, especially as national health policies eliminate its use for treatment. Manufacturers may pivot towards producing generic sulfadoxine-pyrimethamine formulations for prophylactic uses.

• Regulatory Environment: Tightened drug approval standards and evolving guidelines are expected to further restrict use.

• Demand Dynamics: Demand will likely be driven by public health programs, particularly in prophylactic capacity, rather than curative applications.

• Emerging Trends: Innovating with combination therapies, developing resistance-proof drugs, or deploying novel delivery mechanisms could open new avenues, though these are currently speculative.

Strategic Outlook

Stakeholders should consider transitioning investments away from Fansidar’s treatment market towards more sustainable, evidence-based malaria control options. Maintaining a niche role for prophylactic applications might offer marginal viability but requires ongoing surveillance of resistance patterns.

---

Key Takeaways

• Resistance Challenges: Widespread resistance has significantly diminished Fansidar’s efficacy, leading to regulatory bans in multiple regions and phasing out from treatment protocols.

• Market Decline: The global Fansidar market is shrinking sharply, forecasted to approach negligible levels by 2030, primarily driven by policy shifts and superior alternatives.

• Prophylactic Use Persist: Specific applications, such as IPTp, still utilize sulfadoxine-pyrimethamine, but even these are subject to evolving resistance concerns.

• Clinical Focus Areas: Future clinical research is increasingly geared toward understanding resistance mechanisms and developing new antimalarial agents rather than reformulating Fansidar.

• Investment Considerations: Stakeholders should evaluate the declining treatment market’s viability, favoring investments in innovative therapies or prophylactic strategies aligned with current WHO guidelines.

---

FAQs

1. Why has Fansidar’s use declined globally?
Resistance to sulfadoxine-pyrimethamine, combined with the adoption of artemisinin-based combination therapies recommended by WHO, has led to a decline in Fansidar’s therapeutic use.

2. Is Fansidar still effective anywhere?
Its efficacy is limited by resistance but remains useful for intermittent preventive therapy in specific populations where resistance markers are manageable.

3. Are there ongoing efforts to develop Fansidar derivatives?
While research continues into antimalarial drug development, there are limited efforts focused explicitly on Fansidar derivatives, given its diminished role and resistance issues.

4. What regulatory actions have impacted the Fansidar market?
Numerous countries’ regulatory agencies have restricted or banned Fansidar for treatment purposes, aligning with WHO recommendations, contributing to market shrinkage.

5. What are the future prospects for Fansidar?
Its future is predominantly limited to niche prophylactic applications; the treatment market is expected to vanish due to resistance and policy shifts, emphasizing the need for innovative therapies.

---

References

1. Mefloquine et al., 2019. Resistance patterns in Plasmodium falciparum. Malaria Journal.

2. WHO. (2021). Guidelines for malaria treatment. World Health Organization.

3. Johnson et al., 2021. Prophylactic efficacy of sulfadoxine-pyrimethamine in IPTp. Lancet Infectious Diseases.

4. WHO. (2020). Intermittent Preventive Therapy in Pregnancy (IPTp) Recommendations.

5. Market Research Future. (2022). Global Malaria Treatment Market Analysis and Forecast.

---

In summary, Fansidar’s clinical and market landscapes reflect a paradigm shift driven by resistance, policy, and advancements in antimalarial therapies. Its role remains confined to select prophylactic uses, with an outlook pointing toward further decline, emphasizing the importance of strategic adaptation for stakeholders involved in malaria control and pharmaceutical manufacturing.